Alpha 2.0
Login Register
» Articles » PMID: 35172493

Biallelic Deletion of Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition

Overview
Journal JCO Precis Oncol
Specialty Oncology
Date 2022 Feb 17
PMID 35172493
Authors
Munveer S Bhangoo
Carrie Costantini
Brian T Clifford
Jon H Chung
Alexa B Schrock
Siraj M Ali
Samuel J Klempner
Affiliations
Soon will be listed here.
Citing Articles

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.

OSullivan Coyne G, Karlovich C, Wilsker D, Voth A, Parchment R, Chen A Onco Targets Ther. 2022; 15:165-180.

PMID: 35237050 PMC: 8885121. DOI: 10.2147/OTT.S278092.

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway.

Padella A, Fontana M, Marconi G, Fonzi E, Petracci E, Ferrari A Blood Cancer J. 2021; 11(1):7.

PMID: 33414401 PMC: 7791026. DOI: 10.1038/s41408-020-00396-x.

Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.

Krushkal J, Negi S, Yee L, Evans J, Grkovic T, Palmisano A Mol Oncol. 2020; 15(2):381-406.

PMID: 33169510 PMC: 7858122. DOI: 10.1002/1878-0261.12849.

Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.

Klempner S, Bhangoo M, Luu H, Kim S, Chao J, Kim K J Gastrointest Oncol. 2019; 9(6):1198-1206.

PMID: 30603142 PMC: 6286926. DOI: 10.21037/jgo.2018.09.04.

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.

Sigal D, Bhangoo M, Hermel J, Pavlick D, Frampton G, Miller V Oncotarget. 2018; 9(88):35809-35812.

PMID: 30533196 PMC: 6254675. DOI: 10.18632/oncotarget.26260.